Phase 4 MS Clinical Trials

19 active trials · 10 recruiting

19 active phase 4 multiple sclerosis trials are listed here, 10 currently recruiting, sourced from ClinicalTrials.gov.

Phase 4 trials study a treatment that is already approved: long-term safety, use in different groups of patients, or comparisons with other approved therapies.

Active Phase 4 MS trials

RecruitingPhase 4

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Ocrelizumab · Placebo for Ocrelizumab

9 states123 participantsDetails ›

RecruitingPhase 4

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Sponsor: Novartis Pharmaceuticals

ETNATM-ProgMS

224 participantsDetails ›

RecruitingPhase 4

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

60 participantsDetails ›

RecruitingPhase 4

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

Sponsor: Northwestern University

Ublituximab

1 state40 participantsDetails ›

RecruitingPhase 4

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Fingolimod

30 participantsDetails ›

RecruitingPhase 4

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

Sponsor: MGH Institute of Health Professions

Dalfampridine 10 MG [Ampyra] · Physical therapy

1 state48 participantsDetails ›

RecruitingPhase 4

Glucose Consumption in MS Using [F-18]FDG-PET

Sponsor: Brigham and Women's Hospital

[F-18]FDG

1 state50 participantsDetails ›

RecruitingPhase 4

Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities

Sponsor: Oxford University Hospitals NHS Trust

Cryoneurolysis · Botulinum toxin

50 participantsDetails ›

RecruitingPhase 4

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

Sponsor: University of Colorado, Denver

Ozanimod

3 states100 participantsDetails ›

RecruitingPhase 4

Home Based Infusions for Ocrelizumab

Sponsor: University of Colorado, Denver

Ocrelizumab at home

1 state110 participantsDetails ›

By invitation onlyPhase 4

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Sponsor: University of California, San Francisco

Ocrelizumab

1 state5 participantsDetails ›

By invitation onlyPhase 4

Quality Improvement and Practice Based Research in Neurology Using the EMR

Sponsor: Endeavor Health

Listed for each disorder below, up to…

1 state3300 participantsDetails ›

Closed to new patientsPhase 4

Effects of Ocrevus in Relapsing Multiple Sclerosis

Sponsor: Georgia State University

Ocrelizumab · Platform

1 state60 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 4

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Ofatunumab

4 states24 participantsDetails ›

Closed to new patientsPhase 4

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Sponsor: University of California, San Francisco

Ocrelizumab

1 state30 participantsDetails ›

Closed to new patientsPhase 4

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

Sponsor: University of Texas Southwestern Medical Center

Cladribine

2 states40 participantsDetails ›

Closed to new patientsPhase 4

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Sponsor: The Cleveland Clinic

Early Highly Effective Therapies Group · Escalation Therapies Group

8 states800 participantsDetails ›

Closed to new patientsPhase 4

A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis

Sponsor: Bristol-Myers Squibb

BMS-986374

84 participantsDetails ›

MS trials by phase

Phase 2 (60)Phase 3 (49)Phase 1 (43)

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.